MHS

The Perfect Prescription for Profits

By Lawrence Meyers, InvestorPlace Contributor
There’s a lot to be said for going with the category killer in an investment. A merger is creating exactly that in the prescription service space.

Sweet Day for Shipping — Monday’s IP Market Recap

By Kyle Woodley, Senior Investing Editor, Kiplinger
A tiny rise in the Baltic Dry Index spurs big stock gains for several shipping companies.

Walgreen Not Sweating Loss of Express Scripts Customers to CVS — Should It Be?

By Barry Cohen, Health Care Writer
CVS says it could gobble up to 23M prescriptions that Walgreens has sold through Express Scripts if a deal isn't announced. So far, WAG is sticking to its guns.

Campaign to Kill Medco-Express Scripts Deal Likely Futile

By Barry Cohen, Health Care Writer
It's not very likely that major pharmaceuticals will be able to prevent Express Scripts from acquiring Medco. But they do have good reason to try.

Sides Form on Medco-Express Scripts Deal

By Barry Cohen, Health Care Writer
With the Federal Trade Commission likely to give the deal a close eye, analysts and investors sound off varying degrees of optimism and pessimism about this venture.

SFN, Medco Continue to Top Trading

By Anthony John Agnello, Consumer and Technology Writer
Midday Trading Led By SFN Group (NYSE: SFN), Medco Health Solutions (NYSE: MHS), Express Scripts (NASDAQ: ESRX).

Should You Buy Medco Health?

By Peter Cohan, InvestorPlace Writer
Buyout offer from Express Scripts makes this an interesting stock, but absent a bidding war, you might be better off avoiding MHS